Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EW vs GEHC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EW Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

EW Overall Winner 6-Pillar Tally: EW 4 – 2 GEHC Matrix Metrics: EW 6 – 4 GEHC

As of Nov 16, 2026, Edwards Lifesciences Corp (EW) is the stronger overall head-to-head candidate over GE HealthCare Technologies Inc. (GEHC) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). EW carries a Unified Composite Score of 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin), whereas GEHC carries 36.0/100 (SELL) at $83.19 (15.1x Forward P/E, 13.8% operating margin).

  • Composite vs. Pillar Nuance: While GEHC currently prints a higher short-term Unified Composite Score (36.0/100 SELL vs. EW 31.5/100 SELL), EW captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (28.8% vs. 13.8% operating margin) and revenue trajectory (+10.5% vs. +7.2% YoY).
  • Defensive Composite Rating Caution: Although EW compares more favorably head-to-head, both EW (31.5/100 SELL) and GEHC (36.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EW vs GEHC
EW NYSE Head-to-Head Winner
Edwards Lifesciences Corp
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$106.66
-0.46% 1D
Market Cap $60.8B
TTM Revenue $6.67B
Forward P/E 31.6x
Beta / 30D Vol 0.44β · 24% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 50.0 Fund 29.0 Flow 51.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.7% over 20 days), RSI 79
RSI-14: 79.4 · SMA20: $97.03 · SMA50: $90.77
GEHC NASDAQ
GE HealthCare Technologies Inc. Common Stock
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$83.19
+0.2% 1D
Market Cap $37.0B
TTM Revenue $21.6B
Forward P/E 15.1x
Beta / 30D Vol 0.53β · 39% Vol
Unified Composite Score
36.0 / 100 SELL
Tech 20.0 Fund 32.0 Flow 58.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.3% over 20 days), RSI 69
RSI-14: 68.9 · SMA20: $78.24 · SMA50: $70.84

6-Pillar Scorecard Institutional Category Breakdown (EW 4 – 2 GEHC)

Columns: Metric · EW · GEHC
1. Valuation Multiples GEHC
Forward P/E 31.6x 15.1x
Trailing P/E 61.5x 17.3x
PEG Ratio 2.33x 2.21x
EV / Revenue 8.8x 2.1x
2. Growth & Scale EW
Revenue Growth (YoY) +10.5% +7.2%
Earnings Growth (YoY) +6.7% +39.0%
TTM Revenue (USD) $6.67B $21.6B
Market Cap $60.8B $37.0B
3. Profitability & Quality EW
Gross Margin 78.0% 39.3%
Operating Margin 28.8% 13.8%
Net Profit Margin 15.3% 10.0%
Return on Equity (ROE) 9.3% 20.0%
4. Balance Sheet & Cash Flow EW
Cash Generation (TTM) $1.42B $1.89B
Cash Flow Margin 21.3% 8.7%
Net Cash / Leverage $2.41B Net Cash $7.58B Net Debt (0.90x D/E)
Dividend Yield None (0.00%) 0.18%
5. Options & Positioning GEHC
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile 24.6% (34th %ile) 47.7% (6th %ile)
Put/Call OI Skew N/A 0.38x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat EW
OpEx & R&D Intensity 49.2% of Rev ($3.28B) 25.5% of Rev ($5.52B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EW (6) vs GEHC (4)
Institutional Metric EW GEHC Criterion Row Edge
Market Capitalization
Scale
$60.8B $37.0B Larger Scale EW
Trailing P/E Ratio
Valuation
61.5x 17.3x Lower Multiple GEHC
Forward P/E Ratio
Valuation
31.6x 15.1x Lower Multiple GEHC
Revenue Growth (YoY)
Growth
+10.5% +7.2% Higher Growth EW
Operating Margin (TTM)
Profitability
28.8% 13.8% Higher Margin EW
Net Profit Margin
Profitability
15.3% 10.0% Higher Margin EW
Return on Equity (ROE)
Capital Efficiency
9.3% 20.0% Higher ROE GEHC
52-Week Range Position
Momentum
96% ($75–$108) 79% ($59–$90) Stronger Trend EW
Beta / 30D Volatility
Risk Regime
0.44β · 24% Vol 0.53β · 39% Vol Lower Realized Risk EW
Unified Institutional Score
Composite Signal
31.5 / 100 (SELL) 36.0 / 100 (SELL) Higher Composite GEHC
Trailing 12M Revenue (USD)
Operating Scale
$6.67B $21.6B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
78.0% 39.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.33x PEG · 8.8x EV/Rev 2.21x PEG · 2.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.42B ($2.41B Net Cash) $1.89B ($7.58B Net Debt (0.90x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EW +3.59 pp
EW: +23.16% · GEHC: +19.57%
3M Horizon EW +2.7 pp
EW: +17.23% · GEHC: +14.53%
6M Horizon GEHC +5.79 pp
EW: +29.45% · GEHC: +35.24%
1Y Horizon EW +11.4 pp
EW: +23.86% · GEHC: +12.46%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period EW Revenue GEHC Revenue EW Op. Margin GEHC Op. Margin Margin Leader
FY2018 $3.72B N/A 20.1% N/A EW
FY2019 $4.35B N/A 26.4% N/A EW
FY2020 $4.39B N/A 20.5% N/A EW
FY2021 $5.23B $17.6B 32.3% 15.9% EW
FY2022 $4.46B $18.3B 33.6% 13.8% EW
FY2023 $5.01B $19.6B 26.1% 12.5% EW
FY2024 $5.44B $19.7B 25.3% 13.3% EW
FY2025 $6.07B $20.6B 20.8% 13.4% EW

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 24.6%
IV Percentile 34th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GEHC SURGE
8d in phase · OBV DISTRIBUTION
Current IV 47.7%
IV Percentile 6th %ile
Put/Call OI Skew 0.38x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact GEHC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EW Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $60.8B market capitalization and 28.8% operating margin.
OpEx & R&D Reinvestment 49.2% of Rev ($3.28B)
90D Engineering Disclosures 0 Published
GEHC Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $37.0B market capitalization and 13.8% operating margin.
OpEx & R&D Reinvestment 25.5% of Rev ($5.52B)
90D Engineering Disclosures 0 Published

Investor FAQ EW vs GEHC Key Questions & Quantitative Answers

As of Nov 16, 2026, Edwards Lifesciences Corp (EW) is the stronger overall head-to-head candidate over GE HealthCare Technologies Inc. (GEHC) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). EW carries a Unified Composite Score of 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin), whereas GEHC carries 36.0/100 (SELL) at $83.19 (15.1x Forward P/E, 13.8% operating margin). Composite vs. Pillar Nuance: While GEHC currently prints a higher short-term Unified Composite Score (36.0/100 SELL vs. EW 31.5/100 SELL), EW captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (28.8% vs. 13.8% operating margin) and revenue trajectory (+10.5% vs. +7.2% YoY). Defensive Composite Rating Caution: Although EW compares more favorably head-to-head, both EW (31.5/100 SELL) and GEHC (36.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

EW leads the Growth & Scale pillar: EW posts +10.5% YoY revenue growth and +6.7% YoY earnings growth on $6.67B TTM revenue (78.0% gross margin, 28.8% operating margin), compared with GEHC at +7.2% YoY revenue growth and +39.0% YoY earnings growth on $21.6B TTM revenue (39.3% gross margin, 13.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), EW cumulative revenue shifted +63.2% while GEHC shifted +17.2%. In operating R&D and SG&A reinvestment, EW deploys 49.2% of Rev ($3.28B) (0 90-day corporate R&D disclosures) versus 25.5% of Rev ($5.52B) (0 disclosures) for GEHC.

GEHC screens cheaper on headline valuation multiples. EW trades at 31.6x Forward P/E, 61.5x Trailing P/E, 2.33x PEG, and 8.8x EV/Revenue (21.3% FCF margin), whereas GEHC trades at 15.1x Forward P/E, 17.3x Trailing P/E, 2.21x PEG, and 2.1x EV/Revenue (8.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EW (9.3% ROE) versus GEHC (20.0% ROE) capital efficiency.

In options market volatility and institutional positioning, EW carries 24.6% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.44β · 24% Vol realized risk). By comparison, GEHC carries 47.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.38x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.53β · 39% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.